Edition:
United Kingdom

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

19.49USD
19 Jan 2018
Change (% chg)

$0.86 (+4.62%)
Prev Close
$18.63
Open
$18.82
Day's High
$19.49
Day's Low
$18.75
Volume
60,965
Avg. Vol
58,659
52-wk High
$19.49
52-wk Low
$3.13

Latest Key Developments (Source: Significant Developments)

Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences
Wednesday, 27 Dec 2017 

Dec 28 (Reuters) - Catalyst Biosciences Inc ::NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING.  Full Article

Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES INC - ‍PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.1 MILLION SHARES OF COMMON STOCK, OFFERED AT A PRICE OF $9.50 PER SHARE TO PUBLIC​.  Full Article

Catalyst Biosciences Announces Proposed Public Offering Of Common Stock
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES INC - ANTICIPATES USING PROCEEDS FROM OFFERING FOR CLINICAL TRIALS, RESEARCH AND DEVELOPMENT ACTIVITIES, CAPEX.  Full Article

Catalyst Biosciences Appoints Edward Williams To Its Board
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES APPOINTMENT OF EDWARD WILLIAMS TO ITS BOARD OF DIRECTORS.CATALYST BIOSCIENCES INC - BARRY SELICK, WHO HAS BEEN CHAIRMAN SINCE 2006, WILL STEP DOWN FROM BOARD EFFECTIVE FEB. 15, 2018.CATALYST BIOSCIENCES INC - ‍CURRENT BOARD MEMBER AUGUSTINE LAWLOR WILL REPLACE SELICK AS CHAIRMAN​.  Full Article

Catalyst biosciences Q3 loss per share $1.34
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update.Q3 loss per share $1.34.Catalyst Biosciences Inc - ‍phase 1/2 trial of factor IX CB 2679D is advancing with interim results expected by year-end​.Catalyst Biosciences Inc - ‍phase 2 trial of factor Fviia Marzeptacog Alfa (activated) on track for initiation by year-end​.Catalyst Biosciences- ‍believes existing capital resources will be sufficient to meet its projected operating requirements for at least next 12 months​.  Full Article

Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Catalyst Biosciences Inc ::Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration to develop intravitreal anti-complement factor 3 (c3) products for the treatment of dry amd and other retinal diseases.Catalyst Biosciences - ‍under terms of agreement, co, mosaic will collaborate to improve pharmacokinetic (pk) properties of co's anti-c3 proteases​.Catalyst Biosciences Inc - ‍will retain global commercial rights for all collaboration products​.Catalyst Biosciences Inc - ‍for all collaboration products, mosaic will receive product sublicense fees and/or milestone payments and royalties​.  Full Article

Catalyst Biosciences Q2 loss per share $0.42
Thursday, 4 Aug 2016 

Catalyst Biosciences Inc : Catalyst biosciences reports second quarter 2016 financial results and provides corporate update .Q2 loss per share $0.42.  Full Article

Catalyst biosciences, CMC Biologics announce manufacturing agreement
Tuesday, 24 May 2016 

Catalyst Biosciences Inc : Catalyst Biosciences and CMC Biologics announce manufacturing agreement for Catalyst’s next-generation factor VIIA product CB 813D . Catalyst plans to initiate clinical pivotal trial in hemophilia A and B "inhibitor" patients in 2017 . Catalyst Biosciences Inc says remain on track to initiate Phase 2/3 clinical pivotal trial of CB 813D, advanced hemophilia product candidate, in 2017 ."companies committed to establishing manufacturing capabilities for next-generation factor VIIA CB 813D".  Full Article

BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated)

* CATALYST BIOSCIENCES INITIATES PHASE 2/3 TRIAL OF MARZEPTACOG ALFA (ACTIVATED) FOR PROPHYLAXIS IN HEMOPHILIA A OR B WITH INHIBITORS